Pharmacogenomics and Post-Operative Nausea and Vomiting
Status:
Completed
Trial end date:
2019-12-30
Target enrollment:
Participant gender:
Summary
The Researchers overall goal is to evaluate the benefit and utility of preemptive genotypic
data to guide post-operative nausea and vomiting treatment in the bariatric surgical
population. The hypothesis is that using genotypic variation in CYP2D6 to select the
appropriate 5HT3 serotonin receptor antagonist to treat PONV will decrease rates of PONV in
the bariatric surgical population.